220 related articles for article (PubMed ID: 35340663)
1. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.
Hein K; Short N; Jabbour E; Yilmaz M
Blood Lymphat Cancer; 2022; 12():7-16. PubMed ID: 35340663
[TBL] [Abstract][Full Text] [Related]
2. MRD in ALL: Optimization and Innovations.
Pierce E; Mautner B; Mort J; Blewett A; Morris A; Keng M; El Chaer F
Curr Hematol Malig Rep; 2022 Aug; 17(4):69-81. PubMed ID: 35616771
[TBL] [Abstract][Full Text] [Related]
3. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
Short NJ; Jabbour E
Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
[TBL] [Abstract][Full Text] [Related]
4. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
Saygin C; Cannova J; Stock W; Muffly L
Haematologica; 2022 Dec; 107(12):2783-2793. PubMed ID: 36453516
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.
Abou Dalle I; Jabbour E; Short NJ
Ther Adv Hematol; 2020; 11():2040620720910023. PubMed ID: 32215194
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.
Sun YQ; Li SQ; Zhao XS; Chang YJ
Expert Rev Anticancer Ther; 2020 Jun; 20(6):453-464. PubMed ID: 32459519
[TBL] [Abstract][Full Text] [Related]
7. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
9. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
10. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia.
Senapati J; Kantarjian H; Haddad FG; Short NJ; Welch MA; Jain N; Jabbour E
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):333-339. PubMed ID: 38195323
[TBL] [Abstract][Full Text] [Related]
11. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia.
Jen WY; Jabbour E; Kantarjian HM; Short NJ
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38538495
[TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
Logan AC
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101407. PubMed ID: 36517126
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia.
Davydova Y; Galtseva I; Kapranov N; Nikiforova K; Aleshina O; Chabaeva Y; Isinova G; Kotova E; Sokolov A; Troitskaya V; Kulikov S; Parovichnikova E
Diagnostics (Basel); 2022 Dec; 13(1):. PubMed ID: 36611312
[TBL] [Abstract][Full Text] [Related]
14. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
15. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
17. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
18. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
19. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
[TBL] [Abstract][Full Text] [Related]
20. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]